AB
Abbott Laboratories CDR (ABT)
TSX
20.32
-0.11 (-0.54%)
Closed
Aug 25, 2026
Day's Range
20.2920.45
52 wk Range
14.4622.79
Financial Statements - ABT - Abbott Laboratories CDR
Revenue
44.32B▼ 23.6%
Net Income
6.52B▼ 64.8%Net Margin 14.7%
EBITDA
12.02B▼ 19.2%
Free Cash Flow
7.39B▼ 15.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 44.32B | 58B |
| Cost of Goods | 19.31B | 25.86B |
| Gross Profit | 25B | 32.14B |
 Operating Expense | - | - |
| Operating Income | 8.05B | 9.43B |
| Non-Operating Interest | - | - |
| Other Income Expense | 598M | 557.24M |
| Pre Tax Income | 8.46B | 9.69B |
| Income Tax | 1.94B | -8.83B |
| Net Income | 6.52B | 18.53B |
| EPS Basic | 0.488741 | 1.006843 |
| EPS Diluted | 0.483958 | 0.993935 |
| Basic Shares Outstanding | 13.34B | 18.40B |
| Diluted Shares Outstanding | 13.34B | 18.40B |
| Ebit | 8.95B | 10.47B |
| Ebitda | 12.02B | 14.88B |
| Net Income Continuous Operations | 6.52B | 18.53B |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
